-
1
المؤلفون: Vanna Chiarion-Sileni, Pablo Luis Ortiz Romero, Daniil Stroyakovskiy, Rosalie Fisher, Alexander M.M. Eggermont, James Larkin, Paul Lorigan, Axel Hauschild, Micaela Hernberg, Mario Mandalà, Alexander J C van Akkooi, Michal Kicinski, Susana Puig, Nageatte Ibrahim, Lars Bastholt, Victoria Atkinson, Peter Hersey, Pietro Quaglino, Shahneen Sandhu, Christian U. Blank, Georgina V. Long, Anna Maria Di Giacomo, Andrey Meshcheryakov, Naoya Yamazaki, Stefan Suciu, Sandrine Marreaud, Peter Mohr, Ragini R. Kudchadkar, Inge Marie Svane, Matthew Strother, Clemens Krepler, Caroline Robert, Paola Queirolo, Catherine Barrow
المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology
المصدر: Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Testمصطلحات موضوعية: Cancer Research, medicine.medical_specialty, 3122 Cancers, ADJUVANT IPILIMUMAB, MULTICENTER, Pembrolizumab, Placebo, Gastroenterology, 03 medical and health sciences, DOUBLE-BLIND, 0302 clinical medicine, Internal medicine, Medicine, 030212 general & internal medicine, Adverse effect, Melanoma, anti–PD-1, Salvage treatment, Manchester Cancer Research Centre, business.industry, Incidence (epidemiology), ResearchInstitutes_Networks_Beacons/mcrc, NIVOLUMAB, Evaluable Disease, medicine.disease, Confidence interval, 3. Good health, NODE-POSITIVE MELANOMA, Oncology, 030220 oncology & carcinogenesis, SURVIVAL, anti-PD-1, Nivolumab, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927Test
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdfTest -
2
المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology
المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test -
3
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
4
المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer
المصدر: Future Oncology. 16:4429-4438
مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test -
5
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
6
المؤلفون: Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin
المساهمون: University of Zurich, Long, Georgina V
المصدر: Ann Transl Med
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Population, 610 Medicine & health, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Progression-free survival, education, Melanoma, Aged, education.field_of_study, Sulfonamides, business.industry, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Interim analysis, Progression-Free Survival, Clinical trial, Editorial Commentary, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business
وصف الملف: 805_Long_GV._et_al._Epacadostat_plus_pembrolizumab_versus_placebo_plus_pembrolizumab_in_patients_with_unresectable_or_metastatic_melanoma_etc._Lancet_Oncol_2019.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccbTest
https://www.zora.uzh.ch/id/eprint/172887Test/ -
7
المؤلفون: Andrey Meshcheryakov, Alexander M.M. Eggermont, Christian U. Blank, Michal Kicinski, Ragini R. Kudchadkar, Victoria Atkinson, Nageatte Ibrahim, Mario Mandalà, Pablo L. Ortiz-Romero, Inge Marie Svane, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Stefan Suciu, Alexander C.J. van Akkooi, Clemens Krepler, Rosalie Stephens, Caroline Robert, Shahneen Sandhu, Sandrine Marreaud
المصدر: Journal of Clinical Oncology. 39:9500-9500
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, Pembrolizumab, Placebo, Complete resection, Stage III cutaneous melanoma, Gastroenterology, Oncology, Internal medicine, Medicine, Stage III melanoma, Lymph, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b78b72df461dc1b73ea9d7b00a0cabf3Test
https://doi.org/10.1200/jco.2021.39.15_suppl.9500Test -
8
المؤلفون: Scott J. Diede, Reinhard Dummer, Mark M. Jones, Caroline Robert, Lev V. Demidov, James Larkin, Omid Hamid, Tae Min Kim, Georgina V. Long, Jean-Jacques Grob, Tara C. Mitchell, Janet Maleski, Ana Arance, James R. Anderson, Christian Caglevic, Stéphane Dalle, Matteo S. Carlino, Thomas F. Gajewski
المصدر: SSRN Electronic Journal.
مصطلحات موضوعية: Double blind, medicine.medical_specialty, Modified recist, Metastatic melanoma, business.industry, Internal medicine, Medicine, In patient, Epacadostat, Pembrolizumab, business, Placebo, Advanced melanoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9e3c7630dcd1422b6cc3a19bf4a24bb7Test
https://doi.org/10.2139/ssrn.3327362Test -
9
المؤلفون: Jeffrey E. Gershenwald, Merrick I. Ross, Nageatte Ibrahim, Charles H. Yoon, Vernon K. Sondak, Jean-Jacques Grob, Piotr Rutkowski, John M. Kirkwood, Alexander M.M. Eggermont, Andrew Poklepovic, Jason J. Luke, Richard A. Scolyer, Georgina V. Long, Sama Ahsan, Peter Mohr, James R. Anderson, Matteo S. Carlino, Caroline Robert, Axel Hauschild, Paolo A. Ascierto
المصدر: Journal of Clinical Oncology. 37:TPS9596-TPS9596
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Placebo, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Stage II melanoma, Adjuvant therapy, Medicine, In patient, Stage III melanoma, business, Adjuvant, 030215 immunology
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dfd1a33d37748bae5890bfaca892ce80Test
https://doi.org/10.1200/jco.2019.37.15_suppl.tps9596Test -
10
المؤلفون: Mario Mandalà, Andrew Haydon, Stéphane Dalle, Matteo S. Carlino, Paolo A. Ascierto, Christian U. Blank, Victoria Atkinson, Muhammad A. Khattak, Michal Kicinski, Susana Puig, Mikhail Lichinitser, Alexander C.J. van Akkooi, Shahneen Sandhu, Alexander M.M. Eggermont, Stefan Suciu, Nageatte Ibrahim, Georgina V. Long, Clemens Krepler, Caroline Robert, Sandrine Marreaud
المصدر: Journal of Clinical Oncology. 37:2517-2517
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Immunotherapy, Placebo, Predictive value, 03 medical and health sciences, 0302 clinical medicine, Immune system, 030220 oncology & carcinogenesis, Internal medicine, medicine, Stage III melanoma, business, Adverse effect, 030215 immunology
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::79a17e7e77f0a48b2afc7ced78dc55f9Test
https://doi.org/10.1200/jco.2019.37.15_suppl.2517Test